Jordan Health Products III, Inc. v. Osi Holdings I, LLC

New Jersey Superior Court Appellate Division·Decided February 26, 2024·No. A-3028-21·Unpublished

Opinion

NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court ." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited. R. 1:36-3.

SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION

DOCKET NO. A-3028-21

JORDAN HEALTH PRODUCTS III, INC., and ONCOLOGY SERVICES INTERNATIONAL, INC.,

Plaintiffs-Appellants,

v.

OSI HOLDINGS I, LLC, FOUNDERS EQUITY NY, L.P., FOUNDERS EQUITY I, L.P., UPSTATE LINAC SERVICES, LLC, TREMONT ASSOCIATES, LLC, BERNARD AMATO, JOHN CLAYBOURN, RONALD DRAKE, DOMENIC GRECO, RICHARD HALL, SCOTT JOHN, RICKY KREIDER, LES MANN, JOSEPH O'CONNOR, PHILIP PODMORE, JAMES SHARKEY, WARREN STANTON, VINCENT TERRIBILE, and WILLIAM YAEGER,

Defendants-Respondents.

Argued January 17, 2024 – Decided February 26, 2024

Before Judges Whipple, Mayer and Paganelli.

On appeal from the Superior Court of New Jersey, Law Division, Bergen County, Docket No. L-2509-20.

Alfonse R. Muglia argued the cause for appellants (Dentons US LLP, and Jason R. Scheiderer (Dentons US LLP) of the Missouri bar, admitted pro hac vice, attorneys; Erika M. Lopes-McLeman and Jason R.

Scheiderer, on the briefs).

Ari J. Silverman argued the cause for respondents OSI Holdings I, LLC, Founders Equity NY, L.P., and Founders Equity I, L.P. (Paduano & Weintraub LLP, attorneys; Anthony J. Paduano, on the brief).

Daniel Seth Eichhorn argued the cause for respondents Philip Podmore, James Sharkey, Ronald Drake, Vincent Terribile, John Claybourn, Upstate Linac Services, LLC, Rick Kreider, Domenic Greco, William Yaeger, Scott John, Warren Stanton, Les Mann, Bernard Amato and Joseph O'Connor (Cullen and Dykman LLP, attorneys; Daniel Seth Eichhorn, of counsel and on the brief; Ryan P. Duffy, on the brief).

Eric S. Latzer argued the cause for respondent Richard Hall (Cole Schotz PC, attorneys; Cameron A. R. Welch and Eric S. Latzer, of counsel and on the brief).

PER CURIAM Plaintiffs Jordan Health Products III, Inc. (JHP) and Oncology Services International, Inc. (OSI) (collectively, plaintiffs or Buyers) appeal from March 3, 2022 orders granting summary judgment to defendants OSI Holdings I, LLC (Holdings), Founders Equity NY, L.P., Founders Equity I, L.P., Philip Podmore, A-3028-21

James Sharkey, Ronald Drake, Vincent Terribile, John Claybourn, Upstate Linac Services, LLC, Ricky Kreider, Domenic Greco, William Yaeger, Scott John, Warren Stanton, Les Mann, Bernard Amato, Joseph O'Connor, and Richard Hall (collectively, defendants or Sellers). Plaintiffs also appeal from a January 28, 2022 order denying their motion for sanctions against defendants. We affirm all orders on appeal.

This matter arises from a July 6, 2016 Stock Purchase Agreement (SPA)

between plaintiffs and defendants for the sale of OSI. JHP purchased defendants' equity in OSI, a company which sold and serviced medical equipment, for $42.5 million. Defendants signed the SPA in their individual capacity and as the owners of OSI stock.

The sale of OSI was subject to representations and warranties in the SPA.

We recite the provisions in the SPA relevant to this dispute.

Under Section 5.21 of the SPA, entitled "Foreign Corrupt Practices Act,"

defendants represented and warranted that, as of the closing date for the sale of OSI, Sellers had not made any payment "where such payment would constitute a bribe, kickback or illegal or improper payment to assist [OSI] in obtaining products or services or obtaining or retaining business for, or with, or directing business to, any [p]erson."

A-3028-21

Article X of the SPA, entitled "Indemnification," governed Sellers'

obligation to indemnify Buyers. Defendants agreed to indemnify plaintiffs for any "Losses" resulting from a breach of Section 5.21 of the SPA. The term "Losses," defined under Section 1.1 of the SPA, included "any and all losses, liabilities, obligations, damages, judgments, fines, penalties, fees, costs and expenses."

The SPA further provided that a claim for indemnification could arise based on a meritorious third-party action. Thus, Section 10.5 of the SPA required plaintiffs to promptly notify defendants upon "becom[ing] aware of a third party claim which [JHP or OSI] believe[d] [was] likely to result in a [c]laim for indemnification pursuant to this Agreement."

Section 11.5 provided the SPA and all claims arising out of the SPA "shall be governed by and construed in accordance with the laws of the State of Delaware."

Having summarized the relevant provisions of the SPA, we recite the facts pertinent to this appeal.

In May 2019, two related Mexican companies, Centro Oncologico Internacional and Centro Avanzado de Radioterapia (collectively, CART), filed a demand for arbitration. In their arbitration demand, CART alleged a breach

A-3028-21

of contract related to sales agreements in 2012 and 2013 between CART and OSI. CART subsequently amended its arbitration demand to include an allegation that OSI made certain commission payments, which constituted "commercial bribes in violation of New York law."

In a January 15, 2020 letter, sent pursuant to section 10.5 of the SPA, OSI included a third-party claim notice advising defendants of CART's amended arbitration claim, which included an allegation of bribery related to the sale of equipment by OSI. The third-party claim notice acknowledged plaintiffs' entitlement to indemnification under Section 5.21 of the SPA was contingent upon a determination that defendants made a payment constituting "a bribe, kickback or illegal or improper payment."

Shortly after serving the third-party claim notice, OSI learned CART separately filed a criminal complaint in Mexico, alleging OSI committed bribery. As a result, OSI sent a second third-party claim notice to defendants for indemnification. In a March 16, 2020 letter, defendants rejected plaintiffs' demand for indemnification under the SPA.

Based on defendants' denial of plaintiffs' indemnification request, and prior to completion of the arbitration, in April 2020, plaintiffs filed a complaint against defendants in the Superior Court of New Jersey for indemnification

A-3028-21

(State court action) under the SPA. In the complaint, plaintiffs sought to recoup legal fees and expenses associated with defending OSI in the arbitration.

In an August 14, 2020 order, the trial court dismissed plaintiffs' complaint without prejudice. The trial court instructed plaintiffs to refile their complaint after the arbitration, when "damages have accrued [and] are finalized."

The International Centre for Dispute Resolution (ICDR) appointed an arbitrator. The ICDR arbitrator conducted four days of evidentiary hearings. The record of the evidentiary hearing before the ICDR arbitrator included several hundred exhibits and live testimony from witnesses for OSI and CART.

On March 29, 2021, the ICDR arbitrator issued a comprehensive, twenty-

eight-page final award in OSI's favor, denying and dismissing CART's claims in their entirety. While CART alleged OSI committed fraud, bribery, and other transgressions, the ICDR arbitrator concluded CART failed to prove its allegations after a full evidentiary hearing. "[E]ven viewing the record from the most permissive standard of proof," the ICDR arbitrator determined "there [was] no basis in the record even to establish breach or simple negligence on the part of" OSI. The ICDR arbitrator expressly found there were no "kickbacks" or illegal or improper payments by OSI, and CART's "claims fail[ed] for lack of competent proof of their basic elements."

A-3028-21

The ICDR arbitrator concluded CART "failed to prove either that [OSI had] engaged in any misrepresentation or concealment of the commission arrangements." Thus, the ICDR arbitrator's final arbitration award determined "[CART's] claims against OSI [were] without merit in fact or in law and should be denied and dismissed with prejudice on the merits in their entirety ."

Free access — add to your briefcase to read the full text and ask questions with AI

Jordan Health Products III, Inc. v. Osi Holdings I, LLC, (N.J. Ct. App. 2024).

Jordan Health Products III, Inc. v. Osi Holdings I, LLC (Jordan Health Products III, Inc. v. Osi Holdings I, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Davis v. Wakelee
156 U.S. 680 (Supreme Court, 1895)
Scarano v. Central R. Co. Of New Jersey
203 F.2d 510 (Third Circuit, 1953)
Kimball Intern. v. Northfield Metal
760 A.2d 794 (New Jersey Superior Court App Division, 2000)
Aprahamian v. HBO & Co.
531 A.2d 1204 (Court of Chancery of Delaware, 1987)
Flagg v. Essex County Prosecutor
796 A.2d 182 (Supreme Court of New Jersey, 2002)
Ramer v. NJ Transit Bus Operations, Inc.
762 A.2d 297 (New Jersey Superior Court App Division, 2000)
Cummings v. Bahr
685 A.2d 60 (New Jersey Superior Court App Division, 1996)
Pomerantz Paper Corp. v. New Community Corp.
25 A.3d 221 (Supreme Court of New Jersey, 2011)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
Newell v. Hudson
868 A.2d 1149 (New Jersey Superior Court App Division, 2005)
Brill v. Guardian Life Insurance Co. of America
666 A.2d 146 (Supreme Court of New Jersey, 1995)
Kieffer v. Best Buy
14 A.3d 737 (Supreme Court of New Jersey, 2011)
In Re Declaratory Judgment Actions Filed by Various
141 A.3d 359 (New Jersey Superior Court App Division, 2016)
Winshall v. Viacom International Inc.
76 A.3d 808 (Supreme Court of Delaware, 2013)
Terranova v. Gen. Elec. Pension Trust
200 A.3d 412 (New Jersey Superior Court App Division, 2019)
N.M. v. J.G.
605 A.2d 709 (New Jersey Superior Court App Division, 1992)